Hemostemix Inc · TSXV:HEM

Hemostemix — Investor Presentation (July 2023)

23 slides from Hemostemix's investor presentation, Jul 5, 2023

  1. Slide 1: Autologous Stem Cell Therapeutics Q2 Presentation

    Slide 1: Autologous Stem Cell Therapeutics Q2 Presentation

    AUTOLOGOUS STEM CELL THERAPEUTICS Q2 PRESENTATION F Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) © Hemostemix Inc. All Rights Reserved.

  2. Slide 2: Forward-Looking Information

    Slide 2: Forward-Looking Information

    Forward-Looking Information This presentation contains forward looking statements that reflect management’s Actual results, performance and achievement(s) could differ materially from that expectations regarding the future growth and results of operational performance expressed in, or implied by, an

  3. Slide 3: Hemostemix Vision

    Slide 3: Hemostemix Vision

    Global Business Opportunity Hemostemix Vision Hemostemix Vision is to be the first, Compassionate Treatments: 93.5% of most affordable, autologous stem cell ACP-01 treated Limbs were saved from therapy company approved to treat Amputation In Phase II trial. critical limb ischemia and ischemic cardio

  4. Slide 4: Market Size

    Slide 4: Market Size

    Market Size Ischemic Cardiomyopathy $5.7 Billion by 2028 Source: Transparency Research Critical Limb Ischemia (CLI) $3.49 Billion by 2031 Source: Transparency Research 4

  5. Slide 5: The Hemostemix Platform

    Slide 5: The Hemostemix Platform

    The Hemostemix Platform ACP NCP- CCP- -01 01 01 Angiogenic Cell Precursor Neuronal Cell Precursor Cardiomyocyte Cell Precursor Neovascularization at the site of Rebuilds neuronal pathways Rebuilds Heart following Infarct ischemia Homes to site of injury Proposed to Mate with bioscaffold to CLI & PAD

  6. Slide 6: Synergetic Cell Population Becomes ACP-01

    Slide 6: Synergetic Cell Population Becomes ACP-01

    Synergetic Cell Population Becomes ACP-01 Multipotent Cells Enrichment Low Density Cells Confidential

  7. Slide 7: Viability & Mechanism of Action

    Slide 7: Viability & Mechanism of Action

    Viability & Mechanism of Action Parameters Percent Total Cells number 79 Viability 100 % CD34 positive cells 86 ACPs number 86 IL-8 Secretion 96 35 Hours Shelf Life in 98 Syringe

  8. Slide 8: ACP-01 Clinical Trial History

    Slide 8: ACP-01 Clinical Trial History

    ACP-01 Clinical Trial History Clinical Trial Pilot Safety/ Phase 1b Safety Phase 2 Safety Safety and Safety and Type of Study Safety and Feasibility and Efficacy and Efficacy Efficacy Efficacy Feasibility Canada and Bangkok Heart Study Location Thailand Hungary Thailand Thailand United States Hospit

  9. Slide 9: Retrospective ACP-01 Cardiomyopathy Study Results

    Slide 9: Retrospective ACP-01 Cardiomyopathy Study Results

    Retrospective ACP-01 Cardiomyopathy Study Results 53 consecutive patients who underwent transcatheter intramyocardial or intracoronary injection of ACP-01 for the treatment of cardiomyopathy were studied. The pre and post-procedure ejection fraction percentage (EF%), were reported from MUGA scan, SP

  10. Slide 10: Cardiomyopathy Study Highlights

    Slide 10: Cardiomyopathy Study Highlights

    Cardiomyopathy The non-ischemic dilated cardiomyopathy patients (n=8), Study Highlights IMPROVED +14.35% improved from 25.94% before treatment to 40.29% at final follow- up, for an overall improvement of 14.35% (p<0.002) at 12 months. IMPROVED For ischemic heart failure alone +8.37% (n=41), LVEF inc

  11. Slide 11: Changes in LVEF

    Slide 11: Changes in LVEF

    Changes in LVEF Change in LVEF 60 50 40 Pretx n=53 Important Average LVEF 30 Posttx n=52, Overall, upward mobility from one quartile p=0.0007 to the next quartile was significant 20 (p=.0007) for first follow up, and more Final n=35, p=0.0002 significant (p=0.0002) for final follow up. 10 Three of t

  12. Slide 12: ACP-01 7-Day, Scalable Process

    Slide 12: ACP-01 7-Day, Scalable Process

    ACP-01 7-Day, Scalable Process 1 2 3 4 5 6 7 B lood collection Isolation of Culturing and Cell Q uality Control Packaging Administration and shipping SCP d ifferentiation harvesting release tests and shippin g of cells to of cells and batch damaged qualification tissue 12

  13. Slide 13: Key Differentiators of ACP-01

    Slide 13: Key Differentiators of ACP-01

    Key Differentiators of ACP-01 Non-surgical, enhanced cell therapy Simple, cost-effective treatment for restoring circulation to blood production process starved tissues and organs Scalable Low No Patient Ethical Self-donation, means Risks Concerns Stem cells derived no immune rejection or Ready in d

  14. Slide 14: Unique Properties

    Slide 14: Unique Properties

    Unique Properties Non-surgical, enhanced cell therapy treatment for restoring circulation to blood starved tissues and organs Patented peripheral Created from the ACP-01 are cultured in Sourced, Five patent families, blood-based patients own blood, the patients’ serum, processed and including compos

  15. Slide 15: Scalable Production

    Slide 15: Scalable Production

    Scalable Production A Stepped Approach to Automated Scaled Production and Profitability STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 MANUAL SEMI-AUTO F U L LY AU TO M AT E D 20 batches/mo. 40 batches/mo. 60 batches/mo. 72 batches/mo. 80 batches/mo. 4000 batches/mo. l Team 2 Teams 2 Teams 2 Teams 2 Team

  16. Slide 16: Milestones and Scalability

    Slide 16: Milestones and Scalability

    Milestones and Scalability Refractory Angina Non-Risk Adjusted * Ischemic Cardiomyopathy Congestive Heart Risk Adjusted Failure Peripheral Arterial Disease SAM (Current) x 100 * Based on 0.5% North American, European Union Addressable Market. Non- Risk Adjusted Subject to Phase 1: Phase 2: Phase 3 P

  17. Slide 17: Business Advisory Board

    Slide 17: Business Advisory Board

    Business Advisory Board HONORABLE SHELIA COPPS DAVID H. TSUBOUCHI OC, PC B.A., J.D., LL.D., D.S.Litt., C.Dir. Former Deputy Prime Minister of First Japanese Canadian to be Canada, Minister of Environment, elected to any provincial legislature Minister of Heritage and a senior in Canada and to be app

  18. Slide 18: Management & Board of Directors

    Slide 18: Management & Board of Directors

    Management & Board of Directors DR. INA PETE PAVLIN THOMAS DR. FRASER SAREL P.Eng., SMEENK HENDERSON Vice President BA President & PhD, Chief MD, Chief Operations CEO, Co-Founder Scientific Officer Medical Officer & Director DR. RONNIE PETER LACEY LORAN HERSHMAN ICD.D Chairman SWANBERG M.D., F.C.C.S

  19. Slide 19: Scientific Advisory Board Additions

    Slide 19: Scientific Advisory Board Additions

    Scientific Advisory Board Additions DR. NADIA GIANNETTI DR. TERRY HEBERT DR. RENZO CECERE Associate Chief of Medicine Assistant Dean, Director Chief, Division Cardiac Chief of Cardiology McGill Regenerative Surgery, McGill University McGill University Medicine DR. JOHANNES GRILLARI DR. ERNST VON SCH

  20. Slide 20: Takeaways

    Slide 20: Takeaways

    No signs of toxicity or rejection with ACP 01 autologous Over 500 stem cells patients treated with Highly ACP 01 scalable Safely with Statistical Efficacy Takeaways Multiple Little if any indications competing equates to products – multi-billion Hemostemix plus in a class by opportunity Up to itself

  21. Slide 21: Contact

    Slide 21: Contact

    THOMAS SMEENK President, CEO, Co-Founder Contact tsmeenk@hemostemix.com +1-905-580-4170 21

  22. Slide 22: Appendix A: Dr. Fraser Henderson, CMO

    Slide 22: Appendix A: Dr. Fraser Henderson, CMO

    Appendix A Dr. Fraser Henderson Sr., CMO Dr. Fraser Henderson is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is Director of The Metropolitan Neurosurgery Group, LLC, Chief of Neurosurgery at Luminis

  23. Slide 23: Appendix A: Dr. Ina Sarel, CSO

    Slide 23: Appendix A: Dr. Ina Sarel, CSO

    Appendix A Dr. Ina Sarel, CSO • Over 25 years of stem cell therapy discovery and business experience • Mother of Neural Cell Precursors • VP Product Development, Cellect Biotechnology Oct 2017 - Dec 2019 • Vice President R&D, Hemostemix 2011 - Oct 2017 • Director of R&D, Hemostemix 2008 – 2010 • Dir

Source: Internet Archive copy of hemostemix.com

More decks from Hemostemix Inc

All 14 Hemostemix decks